Terms: = Germ cell tumor AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Treatment
30358 results:
1. Long-term outcome and fertility results of intraplacental choriocarcinoma: a retrospective study of 14 patients and literature review.
Liu Y; Song X; Zhang H; Feng F; Zhao J; Yang J; Ren T; Wan X; Jiang F; Li Y; Xiang Y
Orphanet J Rare Dis; 2024 May; 19(1):214. PubMed ID: 38778412
[TBL] [Abstract] [Full Text] [Related]
2. Characteristics and significance of programmed cell death-related gene expression signature in skin cutaneous melanoma.
Wu X; Chen S; Ji Q; Chen H; Chen X
Skin Res Technol; 2024 May; 30(5):e13739. PubMed ID: 38766879
[TBL] [Abstract] [Full Text] [Related]
3. Mortality trend of cutaneous melanoma in Montenegro from 1990-2018.
Nedovic Vukovic M; Terzic Z; Golubovic M; Bojic M; Bukumiric Z
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3463-3472. PubMed ID: 38766804
[TBL] [Abstract] [Full Text] [Related]
4. Risk factor analysis and nomogram development and verification for medullary carcinoma of the colon using SEER database.
Yang L; Yu L; Zhou Q; Liu L; Shen N; Li N
Sci Rep; 2024 May; 14(1):11426. PubMed ID: 38763982
[TBL] [Abstract] [Full Text] [Related]
5. IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma.
Zhao H; Meng L; Du P; Liao X; Mo X; Gong M; Chen J; Liao Y
Biol Res; 2024 May; 57(1):30. PubMed ID: 38760850
[TBL] [Abstract] [Full Text] [Related]
6. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract] [Full Text] [Related]
7. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
8. Singular Value Decomposition-Based Penalized Multinomial Regression for Classifying Imbalanced Medulloblastoma Subgroups Using Methylation Data.
Mohammed I; Elbashir MK; Faggad AS
J Comput Biol; 2024 May; 31(5):458-471. PubMed ID: 38752890
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
10. METTL8 links mt-tRNA m
Lee BWL; Chuah YH; Yoon J; Grinchuk OV; Liang Y; Hirpara JL; Shen Y; Wang LC; Lim YT; Zhao T; Sobota RM; Yeo TT; Wong ALA; Teo K; Nga VDW; Tan BWQ; Suda T; Toh TB; Pervaiz S; Lin Z; Ong DST
Cell Death Dis; 2024 May; 15(5):338. PubMed ID: 38744809
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic nomogram in middle-aged and elderly patients with chordoma: A SEER-based study.
Ouyang C; Sun Y; Li Y; Jiang M; Nong L; Gao G
J Orthop Surg (Hong Kong); 2024; 32(2):10225536241254208. PubMed ID: 38744697
[TBL] [Abstract] [Full Text] [Related]
12. Deciphering the causal relationship between plasma and cerebrospinal fluid metabolites and glioblastoma multiforme: a Mendelian Randomization study.
Zhou Z; Leng H
Aging (Albany NY); 2024 May; 16(9):8306-8319. PubMed ID: 38742944
[TBL] [Abstract] [Full Text] [Related]
13. [Predicting the effectiveness of organ-preserving treatment of choroidal melanoma using optical coherence tomography data].
Stoyukhina AS
Vestn Oftalmol; 2024; 140(2. Vyp. 2):16-20. PubMed ID: 38739126
[TBL] [Abstract] [Full Text] [Related]
14. [A rare cause of hypercorticism: ACTH-secreting pheochromocytoma (a case report)].
Rifai K; Toulali F; Iraqi H; Ettaik M; Gharbi MEH
Pan Afr Med J; 2024; 47():88. PubMed ID: 38737225
[TBL] [Abstract] [Full Text] [Related]
15. EGCG Disrupts the LIN28B/Let-7 Interaction and Reduces Neuroblastoma Aggressiveness.
Cocchi S; Greco V; Sidarovich V; Vigna J; Broso F; Corallo D; Zasso J; Re A; Rosatti EF; Longhi S; Defant A; Ladu F; Sanna V; Adami V; D'Agostino VG; Sturlese M; Sechi M; Aveic S; Mancini I; Sighel D; Quattrone A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732012
[TBL] [Abstract] [Full Text] [Related]
16. Repeat Radiosurgery for Sporadic Vestibular Schwannoma After Primary Radiosurgical Failure: An International Multi-institutional Investigation.
Khandalavala KR; Herberg HA; Kay-Rivest E; Moore LS; Yancey KL; Marinelli JP; Lund-Johansen M; Kosaraju N; Lohse CM; Kutz W; Santa Maria PL; Golfinos JG; Kondziolka D; Carlson ML; Tveiten ØV; Link MJ
Otol Neurotol; 2024 Jun; 45(5):587-593. PubMed ID: 38728563
[TBL] [Abstract] [Full Text] [Related]
17. Targeting Integrin α3 Blocks β1 Maturation, Triggers Endoplasmic Reticulum Stress, and Sensitizes Glioblastoma cells to TRAIL-Mediated Apoptosis.
Kuranaga Y; Yu B; Osuka S; Zhang H; Devi NS; Bae S; Van Meir EG
Cells; 2024 Apr; 13(9):. PubMed ID: 38727288
[TBL] [Abstract] [Full Text] [Related]
18. Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
[TBL] [Abstract] [Full Text] [Related]
19. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract] [Full Text] [Related]
20. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA
Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
[TBL] [Abstract] [Full Text] [Related]
[Next]
